Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. 2022

Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Difficult-to-treat rheumatoid arthritis (D2T RA) is a multifactorial condition in which disease activity of RA persists despite consecutive treatment with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). To evaluate the prevalence and predictive risk factors of D2T RA in our institution, a single-center, retrospective study was conducted. Medical records of RA patients, who visited our hospital from 2011 to 2020 and had a follow-up of more than 6 months, were retrospectively reviewed. D2T RA was defined as RA with a disease activity score of 28 - erythrocyte sedimentation rate (DAS28-ESR) of 3.2 or higher at the last visit, despite the use of at least two b/tsDMARDs. A logistic regression model was used to identify risk factors. A total of 672 patients were enrolled. The mean age at disease onset was 52.1 years and females were dominant (76.3%). After a mean follow-up of 46.6 months, patients with D2T RA accounted for 7.9% of overall patients. Multivariate analysis identified high rheumatoid factor (RF) levels (≥156.4 IU/mL, odds ratio [OR]: 1.95), DAS28-ESR (OR: 1.24), and coexisting pulmonary disease (OR: 2.03) as predictive risk factors of D2T RA. In conclusion, high RF levels, high DAS28-ESR, and coexisting pulmonary disease at baseline can predict the development of D2T RA.

UI MeSH Term Description Entries
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
March 2024, Revue medicale suisse,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
August 2021, Rheumatology (Oxford, England),
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
January 2021, Annals of the rheumatic diseases,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
March 2024, Nature reviews. Rheumatology,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
January 2022, Frontiers in medicine,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
November 2023, International journal of rheumatic diseases,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
January 2021, RMD open,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
June 2024, Rheumatology (Oxford, England),
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
December 2023, Scandinavian journal of rheumatology,
Ryu Watanabe, and Motomu Hashimoto, and Koichi Murata, and Kosaku Murakami, and Masao Tanaka, and Koichiro Ohmura, and Hiromu Ito, and Shuichi Matsuda
March 2023, Annals of the rheumatic diseases,
Copied contents to your clipboard!